Testosterone therapy is having a moment. The science hasn’t caught up.

The Pentagon is preparing to screen service members for low testosterone. The Trump administration wants the FDA to loosen who qualifies for hormone therapy. And between podcast ads, Instagram clinics, and RFK, Jr.’s public enthusiasm for testosterone injections, more men are asking for a prescription than ever. As Will Stone reported for NPR, the evidence on who actually benefits hasn’t kept pace with the hype.

Testosterone therapy does work, for the right patient. A 2023 trial published in the New England Journal of Medicine, called TRAVERSE, followed middle-aged and older men using testosterone gel and found no increased risk of heart attack or stroke compared with placebo, as long as levels stayed within a normal range. It did flag a higher risk of bone fractures, a reminder that “safe” is relative.

Mis- and disinformation are distorting science and public policy. Subscribe to our Daily and Weekly Digests for incisive coverage of ‘disruptive’ innovations in AI, agricultural biotechnology, food, chemicals, nuclear energy, vaccines, and other disruptive innovations.

The Deficiency Problem

The bigger issue is diagnosis, not the drug. A 2022 study in JAMA Internal Medicine sent secret shoppers with normal testosterone levels to direct-to-consumer clinics. Most got prescribed anyway.

“Now these benefits apply only to men who have low testosterone, unequivocally low testosterone,” Dr. Peter Snyder, an endocrinologist at the University of Pennsylvania, told NPR. “The lower, the more likely are the benefits.”

Dr. Helen Bernie, director of Sexual and Reproductive Medicine at Indiana University, puts it more bluntly. “The goal of testosterone therapy isn’t peak performance,” she says. “It’s not some drug to promise the fountain of youth. It is restoring normal physiology in men who have a true deficiency. I think it’s really important to separate marketing from actual medicine.”

Pete Hegseth hormone replacement therapy article cover image
Related on the SLP
Pete Hegseth’s bizarre Viagra commercial as Trump administration endorses ‘hormone replacement therapy’

That distinction matters more as the FDA weighs expanding access. Widening the criteria without fixing how clinics screen patients could mean more men on testosterone who were never deficient in the first place, chasing symptoms — fatigue, low libido, a few extra pounds — that have plenty of other causes.

Testosterone therapy isn’t a scam, and it isn’t a miracle. It’s a treatment for a specific, diagnosable condition. The politics may be moving fast, but the biology, as usual, is taking its time.

Read the original article here

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Bayer Crop Circle in Golden Wheat
Making fertilizer from thin air: Bayer’s gene-editing innovation could dramatically cut chemical fertilizer use in growing food
Picture1
Viewpoint: How badly is the U.S. food-safety net fraying? FDA’s bungled handling of the tainted lettuce crisis deepens concerns over cuts to disease tracking and response
Screenshot-2026-11-03-at-12.31.18-PM
Gene editing once viewed with suspicion by UK  farmers, upwards of 90% now open to their sustainability benefits
Reaching Through the Woven Sky
Challenging genetic modification rejectionists: Our evolving food system has relied on science for thousands of years
Smiling-Woman-Over-Teal-Abstract-Shapes
Viewpoint: RFK Jr.’s latest foray into junk science: Even Kennedy’s hand-picked NIH director balks at appointment of crackpot mental health director
Neon Genome_ Fetal Dreamscape
The race to genetically engineer babies
Glossy Plastic Bag of Tokens and Labels
Viewpoint: How CNN got played by environmental activists pushing a plastics scare and litigation agenda
Screenshot-2026-10-29-at-11.18.34-AM
Viewpoint: ‘Just the flu’: Skipping your child’s flu shot could be a fatal mistake
ChatGPT-Image-Mar-10-2026-01_39_01-PM
Viewpoint—“Miracle molecule” debunked: Why acemannan supplements don’t work
Screenshot-2026-11-02-at-11.34.28-AM
Farmers are collateral damage in the PFAS “forever chemicals” crossfire. Here’s what they need to know.
Screenshot 2026-10-27 at 10.32
“Do your own research”: What Medicare’s annual open enrollment circus teaches us about the seductive trap of DIY health and science
Red and Green Embroidered Campaign Caps
Viewpoint: The fragile (and often bizarre) MAHA-MAGA-far left health-and-chemicals coalition is fracturing. Here’s why
Screenshot-2026-10-28-at-3.00.44-PM
Viewpoint: Activist attacks on corporations increasingly depend on "attribution" science to target oil companies for global climate change
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.